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In this paper the authors present information on the study of heart rate variability of patients with chronic kidney disease.  
Hypersympathicotonia is observed in patients with renal disease and hypertension. Arguments are given in favor of the use of angiotensin-
converting enzyme. The issue of the place of beta-blockers is debated.
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in recent years, more attention has been given to identifying predictors 
of sudden death in patients with chronic 
kidney disease: glomerulonephritis, a 
heart rhythm disorder, the presence of 
concomitant coronary artery disease 
and hypertension. Monitoring of blood 
pressure and heart rate helps to clarify 
aspects of the pathogenesis of the 
disease, prescribe adequate treatment 
to nephrology patients and prevent 
complications of the cardio-vascular 
system..
This paper presents the results of a 
study of heart rate variability (HRV) in 
patients with chronic kidney disease 
of I-III stages: glomerulonephritis, the 
dynamics of these parameters under the 
influence of antihypertensive therapy, 
the appropriateness of the use of beta-
blockers (nebivolol) and/or ACE 
inhibitors (perindopril).We have studied 
patients with chronic kidney disease 
(glomerulonephritis; hypertensive), who, 
unlike healthy ones, faced prevalence 
of sympathetic tone, accompanied by a 
temporary decrease in HRV.Thus, the 
daily value of SDNNi, characterizing 
the total HRV, was on average by 
41.1% lower than in the healthy group, 
in the passive period - by 94.23% 
during the active period - at 41.26 
(p < 0.001). Accurate daily measurementof 
theheart rateintervaldifference, rMSSD, 
was 42.64% lower in patients with 
hypertension than in those without, 
respectively rMSSD in the active period 
was lower by 42,33%, rMSSD in the 
passive period - by 53.23% (p < 0.001).
The average value of pNN50 among 
three subgroups of patients was reduced 
by 70,45%, pNN50 during the active 
period - at 62.13% and pNN50 in the 
passive period - by 72.58% compared to 
the healthy group (p < 0.001).
HF daily index reflecting the 
influence of the parasympathetic 
division of the ANS on cardiac activity 
was lower by an average of 41.42% 
as compared to healthy individuals, 
respectively HF during the active period 
was at 42.15% in the passive period - 
at 43.72%.  
In contrast, the daily out put was 
higher for low frequency spectrum night 
LF, reflecting thes ympa the ticinfluence 
on the heart rate: respectively, inaverage – 
at 14.64%, the active period – at 21.15%, 
in the passive period - 3.12% (p < 0.001) 
as compared with the group of healthy .
In the main group sympathetic/
parasympathetic balance offset was also 
observedin favor of the sympathetic 
division of the ANS, the rate of daily 
LF/HF was high erby an average of 
49.34%, i.e. patients with hypertension 
showed the predominance of sympathetic 
activity.
In a study of 17 patients in the 
control group receiving antihypertensive 
drug enalapril maleate 20mg twice a 
day, it was found out that its influence 
has improved baroreflex regulation of 
hemodynamics, reduced sympathetic 
activity.
When comparing the percentage of 
fluctuations of high, low and very low 
frequencies of patients in the control 
group we marked the decline in the 
percentage of slow - wave 1 - the first 
order with 16,72 ± 2,07 to 13,27 ± 2,12; 
slow waves of 2 order - with 51,18 ± 6,94 
to 45,90 ± 6,46, increase in the proportion 
of tidal waves from 32,27 ± 6,77 to 
40,81 ± 7,57 (Fig.1, Table 1).
Under the influence of enalapril 
maleate in the control group, there was 
a significant decrease in both systolic 
blood pressure by 26.08 mm Hg and 
diastolic – by 13.90 mm Hg (Table 2).
Tab. 1
Dynamics of changes in the spectral parameters of HRV in patients of the control group (n = 17)  
under the influence of enalapril maleate
Before treatment After treatment p I-II
LF M ± m, мс2 1190±304 420±213 p < 0,05
VLF M ± m, мс2 4698±1540 1212±616 p < 0,05
HF M ± m, мс2 1416±323 769±299 p < 0,05
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Stable positive effect in hypertensive 
patients in the control group was 
accompanied by subjective improvement 
of a general state (decreasing intensity 
of the brain and anginal pain, memory 
improvement, decrease of the overall 
weakness etc.) and was confirmed by 
echocardiography (reduction of left 
ventricular hypertrophy in 48% of 
patients), electrocardiogram (the tendency 
to normalization of the ST segment in 
51% of patients).
The decrease in sympathetic 
nervous system in patients with 
glomerulonephritis under the influence 
of ACE inhibitor treatment is a positive 
predictor in the progression of chronic 
kidney disease.Correction of autonomic 
imbalance with enalapril maleate is 
suitable both in the complex treatment 
of patients with chronic kidney disease 
and in the prevention of cardio-vascular 
complications in the rehabilitation of 
nephrology patients.There was a relation 
between the magnitude of blood pressure 
and weakening of baroreflex regulation 
with increased sympathetic influences 
(in patients with severe hypertension 
power VLF increases, the power of 
LF-components therein is low).
Under the influence of 
antihypertensive therapy along with anti-
hypertensive effect there was a positive 
change of HRV. In the study group 
Fig. 1. Percentage of LF, VLF, HF patients in the control group
(n = 32) treated with perindopril 
reduction of clinical manifestations 
of the underlying disease, lowering 
blood pressure, the positive dynamics 
of the autonomic regulation of the 
cardiovascular system was observed 
(Table 3), namely the reduction of 
sympathetic activity (reduction of 
low-frequency power of the spectral 
components of heart rate - VLF from 
51,64±13,98% to 35,38±11,56%) and 
an increase in parasympathetic activity 
(increased power of high-frequency 
components - HF from 28.67±9,54% to 
31.34±9.54%).An effect on the baroreflex 
regulation is marked: the capacity of the 
midrange spectrum component has been 
increased - LF from 21.34±8.05% to 
28.38±9.54%, p < 0.05.
In the group of patients (n = 34) 
treated with nebivolol reduction of 
the clinical manifestations of the 
underlying diseasewas also observed; 
antihypertensive effectwas received. 
According to cardiointervalography (Table 
4) there was a decrease in sympathetic 
activity - VLF from 42,28±10,06% 
to 32,79±10,06%, p < 0.05, and an 
increase in parasympathetic activity - HF 
from 32,46±10,06% to 42,56±10,06%, 
p < 0.05. There was no effect on 
baroreflex regulation - LF (p > 0.1).
Tab. 2
Dynamics of changes in systolic and diastolic blood pressure in patients in the control group (n = 17)  
under the influence of enalapril maleate
Kind of blood pressure Before treatment After treatment p I-II
Systolic 160,00±28,16 133,92±15,39 p < 0,05
Diastolic 93,70±13,22 79,80±7,70 p < 0,05
Tab. 3
Dynamics of HRV in patients with chronic kidney disease (glomerulonephritis)  
who received ace inhibitors, perindopril
Index Cardiointervalographiс
Chronic kidney disease: glomerulonephritis, perindopril
P
Before treatment (M±σ) After treatment (M±σ)
LF,% 21,34±8,05 28,38±9,54 p < 0,05
VLF, % 51,64±13,98 35,38±11,56 p < 0,05
НF,% 28,87±9,54 31,34±9,54 p < 0,05
Sympathetic- vagal index, LF/ HF 0,74±0,07 0,86±0,07 p < 0,05
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At 6 months after the combined 
treatment (perindopril+nebivolol) 
alignment of the balance between 
sympathetic and parasympathetic 
divisions of the autonomic nervous 
systemwas observed. 
This was observed in a statistically 
significant (p<0,001) increase of the 
time parameters of ANS: SDNNidaily 
in a group of perindopril+nebivololhas 
increased by 35.8% - more than in the 
control group (standard) - by 32.2%, 
SDNNiin active period - at 32.76%, in 
the control group at 28.3%, SDNNiin 
passive period - 36.23% (27.5%) 
(p<0.001).Daily SDNN in a group of 
perindopril+nebivololhas increased by 
34.3% (control – 23.6%), SDNN during 
the active period has increased by 33.1% 
(control - by 22.2%), SDNN in the 
passive period has increased by 19.3% 
(control - 11.8%). Other timeparameters 
changedsimilarly: dailyrMSSDhas 
decreasedby 54.5% (control - 39.8%), 
rMSSDin the active periodhas increased 
by51.33% (control-45.6%), rMSSDin 
apassiveperiod has increased by 
57.23% (control - 39.4%, p < 0.001).
Under the influence ofthe antihypertensive 
therapysympathetic-parasympathetic 
balancehas returned to normal inmost 
patients (decline by 34.45% in the group 
of perindopril+nebivolol; by 39.2% in 
the control group).
HF indicator, showing the effect of 
parasympathetic cardiac activity grew by 
38.9%, in the control group - by 32.4%, 
the power spectrum of low frequencies, 
on the contrary, tended to lower: in 
the group with perindopril+nebivolol 
by 23.4%, in the controlgroup - 
by 15.4%.
No statistically significant differences 
between the groups of perindopril, 
Fig. 2. Dynamics of HRV in patients with chronic kidney disease 
(glomerulonephritis) who received ACE inhibitors, perindopril, nebivolol
nebivolol and perindopril+nebivolol were 
fixed, but the trend towards normalization 
in the perindopril+nebivololgroupwas 
more expressed in comparison with the 
groups of perindopril and control. The 
use ofenalaprilled to positive changes 
observed in the HRV perindopril group 
(Figure 2).
It should be noted that the 
effectiveness of treatment of 
vasoregulatory disorders was higher in 
patients with chronic kidney disease 
at the stage I: glomerulonephritis. 
In patients with nephrotic form and 
pronounced chronic kidney disease at 
the stage III: glomerulonephritis, in 
34.5% of cases it was failed to achieve 
the correction of autonomic regulation. 
Thus, the research has revealed 
signs of autonomic dysfunction in 
patients with chronic kidney disease: 
glomerulonephritis with hypertension. 
Its incidence increases with the 
decrease in the glomerular filtration 
rate. Autonomic imbalance manifests 
dominatinghypersympathicotonia. 
Nebivolol therapy with perindopril 
enforced under vegetative-normalizing 
and vegetative-corrective effects, and 
perindopril+nebivolol provide both 
vegetative normalization and vegetative 
correction, manifested through the 
reduced and stabilized blood pressure.
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